Trifluoperazine: Difference between revisions
No edit summary |
|||
| Line 63: | Line 63: | ||
Trifluoperazine is not approved for the treatment of dementia-related behavior problems. Typical (First-generation) antipsychotic agents may increase mortality in such patients. Most fatalities appeared to result from cardiovascular-related events (e.g. heart failure, sudden death) or infectious (mostly pneumonia). | Trifluoperazine is not approved for the treatment of dementia-related behavior problems. Typical (First-generation) antipsychotic agents may increase mortality in such patients. Most fatalities appeared to result from cardiovascular-related events (e.g. heart failure, sudden death) or infectious (mostly pneumonia). | ||
==Side Effects== | |||
Extrapyramidal symptoms (EPS) are frequent, especially at doses exceeding 6 mg daily. These symptoms include: | |||
*Drooling/trouble swallowing | |||
**Restlessness/constant need to move | |||
- Shaking (tremor) | |||
- Shuffling walk | |||
- Stiff muscles | |||
- Severe muscle spasms/cramping (such as twisting neck, arching back, eyes rolling up) | |||
- Mask-like expression of the face | |||
- Tardive dyskinesia (any uncontrollable movements such as lip smacking, mouth puckering, tongue thrusting, chewing, or unusual arm/leg movements | |||
Other adverse effects of trifluoperazine include the following: | |||
Revision as of 00:05, 27 October 2020
[[Category: ]] Drug Class: Antipsychotics, typical; Antipsychotic 1st Generation
Trifluoperazine (中文:[[ ]]) is a typical antipsychotic or 1st Generation antipsychotic medication. It is used to treat
- Schizophrenia
- Short-term adjunctive management of severe anxiety
- Severe nausea and vomiting
It helps patient to think more cleaerly, feel less nervous, and take part in everyday life. It can reduce aggressive behavior and the desire to hurt oneself/others. It helps to decrease hallucinations.
Pronunciation
Trifluoperazine 1mg
Drug Names
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Trifluoperazine Tab 1 mg | TRIF01 | P1S1S3 |
| Trifluoperazine Tab 5 mg | TRIF02 | P1S1S3 |
Mechanism of Action
Trifluoperazine has central antiadrenergic, antidopaminergic, and minimal anticholinergic effects. It works by blocking postsynaptic mesolimbic dopamine D1 and D2 receptors in the brain, minimizing such symptoms of schizophrenia as hallucinations, delusions and disorganized thought and speech. Antiemetic effects are attributed to dopamine receptor blockade in the medullary chemoreceptor trigger zone. The presumed effectiveness of antipsychotic drugs relied on their ability to block dopamine receptors. This assumption arose from the dopamine hypothesis that maintains that both schizophrenia and bipolar disorder are a result of excessive dopamine activity.
Dosage
| Indication | Dose |
|---|---|
| Schizophrenia | By mouth
ADULT:
|
| Short-term adjunctive management
of severe anxiety |
By mouth
ADULT:
ELDERLY:
|
| Severe nausea and vomiting |
By mouth ADULT:
|
Trifluoperazine is not approved for the treatment of dementia-related behavior problems. Typical (First-generation) antipsychotic agents may increase mortality in such patients. Most fatalities appeared to result from cardiovascular-related events (e.g. heart failure, sudden death) or infectious (mostly pneumonia).
Side Effects
Extrapyramidal symptoms (EPS) are frequent, especially at doses exceeding 6 mg daily. These symptoms include:
- Drooling/trouble swallowing
- Restlessness/constant need to move
- Shaking (tremor) - Shuffling walk - Stiff muscles - Severe muscle spasms/cramping (such as twisting neck, arching back, eyes rolling up) - Mask-like expression of the face - Tardive dyskinesia (any uncontrollable movements such as lip smacking, mouth puckering, tongue thrusting, chewing, or unusual arm/leg movements Other adverse effects of trifluoperazine include the following:
